New targeted drug aims to outsmart Hormone-Resistant breast cancer

NCT ID NCT07648914

Recruiting now Disease control Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 3 times

Summary

This phase 3 trial compares an experimental drug called BL-B01D1 to standard chemotherapy in people with a common type of breast cancer (HR+/HER2-) that has stopped responding to hormone therapy and cannot be removed by surgery. The study aims to see if BL-B01D1 can delay cancer growth or improve survival. Participants are randomly assigned to receive either the new drug or one of several standard chemotherapies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BL-B01D1 (izalontamab brengitecan)
What this could lead to: If successful, this could offer a new targeted treatment option for people with HR+/HER2- breast cancer whose disease has progressed after endocrine therapy.
What could go wrong: This is an early-phase trial, and the drug may not prove more effective or safer than standard chemotherapy. Side effects from the investigational drug are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Cancer Hospital Chinese Academy of Medical Sciences
RECRUITING

Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.